This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme is expected to provide updates on the development of its pipeline candidates during Q4 earnings call.
What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
Will Mylan (MYL) Disappoint Investors This Earnings Season?
by Zacks Equity Research
During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
by Zacks Equity Research
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
by Zacks Equity Research
AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.
Roche's Rituxan Gets Priority Review for Label Expansion
by Zacks Equity Research
FDA accepts sBLA and grants priority review for Roche Group's (RHHBY) leukemia drug Rituxan.
Exelixis Reports Positive Data From Thyroid Carcinoma Trial
by Zacks Equity Research
Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
by Zacks Equity Research
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate
by Zacks Equity Research
Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
Biogen Halts Tysabri Development in Stroke as Study Fails
by Zacks Equity Research
Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.
Array's Melanoma Combo Shows Positive Overall Survival Data
by Zacks Equity Research
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Roche Reports Positive Data From Tecentriq-Avastin Study
by Zacks Equity Research
Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.
Top Analyst Reports for Apple, Visa, Chevron & Altria
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Apple (AAPL), Visa (V), Chevron (CVX) and Altria (MO).
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.
Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
by Swarup Gupta
Losses on Wall Street and falling bond yields weighed on global markets this week.
Puma, CANbridge Team Up to Commercialize Nerlynx in China
by Zacks Equity Research
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
by Zacks Equity Research
Roche reported strong sales for 2017 buoyed by performance of new drugs ??? Tecentriq, Alecensa and Perjeta which offset the decline in Tarceva and Avastin.